LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

Search

VIRIDIAN THERAPEUTICS INC

Closed

SectorHealthcare

19.16 7.04

Overview

Share price change

24h

Current

Min

17.79

Max

19.58

Key metrics

By Trading Economics

Income

-14M

-101M

Sales

3K

75K

Profit margin

-134,313.333

Employees

143

EBITDA

-14M

-100M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+111.99% upside

Dividends

By Dow Jones

Next Earnings

11 lis 2025

Market Stats

By TradingEconomics

Market Cap

103M

1.5B

Previous open

12.12

Previous close

19.16

News Sentiment

By Acuity

23%

77%

50 / 372 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

VIRIDIAN THERAPEUTICS INC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 wrz 2024, 20:38 UTC

Acquisitions, Mergers, Takeovers

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

10 wrz 2024, 14:42 UTC

Acquisitions, Mergers, Takeovers

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

Peer Comparison

Price change

VIRIDIAN THERAPEUTICS INC Forecast

Price Target

By TipRanks

111.99% upside

12 Months Forecast

Average 38.2 USD  111.99%

High 50 USD

Low 26 USD

Based on 11 Wall Street analysts offering 12 month price targets forVIRIDIAN THERAPEUTICS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

12 / 13.14Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

50 / 372 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$